CN111227046B - Application of dairy product in improving infant intestinal SIgA level - Google Patents
Application of dairy product in improving infant intestinal SIgA level Download PDFInfo
- Publication number
- CN111227046B CN111227046B CN202010104555.6A CN202010104555A CN111227046B CN 111227046 B CN111227046 B CN 111227046B CN 202010104555 A CN202010104555 A CN 202010104555A CN 111227046 B CN111227046 B CN 111227046B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- use according
- powder
- dairy product
- providing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 44
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 17
- 241001591005 Siga Species 0.000 title claims abstract 7
- 239000000843 powder Substances 0.000 claims abstract description 93
- 239000000463 material Substances 0.000 claims abstract description 55
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 47
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 30
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010076119 Caseins Proteins 0.000 claims abstract description 29
- 102000011632 Caseins Human genes 0.000 claims abstract description 29
- 235000013336 milk Nutrition 0.000 claims abstract description 29
- 239000008267 milk Substances 0.000 claims abstract description 29
- 210000004080 milk Anatomy 0.000 claims abstract description 29
- 235000021247 β-casein Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 22
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 22
- 235000018102 proteins Nutrition 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- 239000005862 Whey Substances 0.000 claims abstract description 13
- 230000002159 abnormal effect Effects 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 208000026278 immune system disease Diseases 0.000 claims abstract description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 235000020244 animal milk Nutrition 0.000 claims abstract description 7
- 235000019197 fats Nutrition 0.000 claims description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 238000001694 spray drying Methods 0.000 claims description 13
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000007580 dry-mixing Methods 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011707 mineral Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 8
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical group OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 8
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 7
- 239000002285 corn oil Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 claims description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 6
- 235000019743 Choline chloride Nutrition 0.000 claims description 6
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 6
- 229960003178 choline chloride Drugs 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 5
- 229940096898 glyceryl palmitate Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000008347 soybean phospholipid Substances 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 235000019737 Animal fat Nutrition 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 241000282994 Cervidae Species 0.000 claims description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims 7
- 108090000942 Lactalbumin Proteins 0.000 claims 7
- 235000021241 α-lactalbumin Nutrition 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 abstract description 3
- 241001134770 Bifidobacterium animalis Species 0.000 abstract description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 abstract description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 abstract description 3
- 241000186012 Bifidobacterium breve Species 0.000 abstract description 3
- 241001608472 Bifidobacterium longum Species 0.000 abstract description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 abstract description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 abstract description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 abstract description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 abstract description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 abstract description 3
- 229940009291 bifidobacterium longum Drugs 0.000 abstract description 3
- 235000013350 formula milk Nutrition 0.000 description 23
- 235000020256 human milk Nutrition 0.000 description 16
- 210000004251 human milk Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 8
- 235000008939 whole milk Nutrition 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 5
- 241000723343 Cichorium Species 0.000 description 4
- 235000007542 Cichorium intybus Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 235000020238 sunflower seed Nutrition 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- 125000005457 triglyceride group Chemical group 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000011359 Chromosome disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000003031 feeding effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 235000020122 reconstituted milk Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
Abstract
The invention belongs to the field of food or medicine, and discloses application of a dairy product in preparing food or medicine for improving the level of infant intestinal SIgA, or preparing food or medicine for preventing or treating immune diseases or gastrointestinal diseases caused by abnormal infant intestinal SIgA level; wherein the dairy product comprises: a protein-providing material, a fat-providing material and bifidobacteria; wherein the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains a-whey protein and beta-casein; the raw material for providing the fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains more than 15% by weight of Sn-2 palmitic acid glyceride calculated by the palmitic acid; the Bifidobacterium is selected from at least one of Bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and Bifidobacterium infantis.
Description
Technical Field
The invention belongs to the field of food or medicine, and particularly relates to an application of a dairy product in improving the intestinal SIgA level of infants.
Background
Secretory immunoglobulin A (SIgA) is an important immune substance in breast milk, has the functions of resisting acid, being not easy to be hydrolyzed by proteases in the digestive tract, being capable of being combined with digestive tract mucosal cells to effectively protect the mucosa and the like, and plays an immune role in the digestive tract of infants. SIgA is an important influencing factor in the improvement of the immune system in infants. Researches show that the infant formula can improve the intestinal SIgA level of infants and reduce the risks of immunological diseases and gastrointestinal diseases, such as allergy, inflammatory bowel disease and the like [1] . Celiac disease is an autoimmune disease with heredity and occurs in the small intestine, and symptoms include chronic diarrhea, growth retardation, fatigue, etc. caused by the attack of the small intestine villi by the immune system. The clinical research finds that [2] While the intestinal microbiota of healthy infants is characterized by an increased bacterial diversity, infants with celiac disease excrete lower amounts of SIgA, with markedly abnormal levels of SIgA. It also proves that [3] The dynamic balance of SIgA and intestinal microbiota can make the immune system of human body operate well, effectively resist infection and disease, and avoid the initiation of autoimmune disease. The infant with rotavirus enteritis can achieve the treatment effect after taking the immunoglobulin auxiliary probiotics, and gradually recover the abnormal SIgA level caused by bacterial infection [4] 。
At present, there is a need for a food or a medicine capable of improving the SIgA level in the infant intestinal tract, and preventing or treating immune diseases or gastrointestinal diseases caused by abnormal SIgA level in the infant intestinal tract.
The breast milk fat provides 45-60% of energy for the early growth of infants, and more than 98% of the breast milk fat is triglyceride. The positions of different fatty acids in the breast milk esterified with glycerol are different; wherein unsaturated fatty acids such as linoleic acid and alpha-linolenic acid in the breast milk are more than 1 site and 3 sites of the triglyceride; long chain saturated fatty acids such as palmitic acid in breast milk are mainly located at the 2-position, and thus formed palmitic acid triglyceride is called Sn-2 palmitic acid triglyceride. In the digestive tract, the lipolytic enzymes of the infant's stomach act primarily on the 1-and 3-ester bonds of triglycerides, so that unsaturated fatty acids are first freed and then degraded and absorbed in the duodenum along with Sn-2 palmitic acid monoglyceride. However, the common infant formula powder contains palm oil, most of long-chain saturated fatty acids of the palm oil are esterified on ester bonds at the 1-position and the 3-position of triglyceride, and the palm oil is easy to combine with calcium ions after hydrolysis to form calcium soap, so that the absorption of fat and mineral substances is reduced, and the calcium soap which is difficult to absorb can also cause hard excrement to cause difficult defecation. The national standard GB14880 allows OPO structural ester to be added into infant formula powder, which is a food raw material rich in Sn-2 palmitic acid triglyceride, and the content of Sn-2 palmitic acid triglyceride in the product can be increased by adding the OPO structural ester. Animal studies comparing the effect of feeding different proportions of SN-2 palmitic acid (40% in 12% vs higher by 56%) on the intestinal microbiota of rats, 16 srna sequencing results showed no significant difference in the composition of the intestinal microbiota of the three groups of animals.
Breast milk is rich in a-lactalbumin, a protein rich in essential amino acids, which is digested to produce a variety of biologically active polypeptides. Researches show that the a-lactalbumin digestion product can inhibit pathogenic bacteria such as escherichia coli, pneumococcus, staphylococcus aureus, candida and the like in vitro.
Beta-casein is a casein molecule with the highest content in breast milk, and a polypeptide fragment generated by digestion has the effect of inhibiting the growth of harmful bacteria.
Probiotics are an important component of the gut microbiota. The definitions of probiotics by the world Food and Agriculture Organization (FAO) and the World Health Organization (WHO) are: live bacteria which can exert an effective effect on the health of the consumer can be ingested in an appropriate amount. The bifidobacterium is one of probiotics, and the currently common bifidobacterium strains comprise bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis and the like, and a plurality of novel strains.
Disclosure of Invention
The invention provides an application of a dairy product in improving the infant intestinal SIgA level or preventing or treating immune diseases or gastrointestinal diseases caused by abnormal infant intestinal SIgA level.
The invention relates to an application of a dairy product in preparing food or medicine for improving the SIgA level of infant intestinal tracts or preparing food or medicine for preventing or treating immune diseases or gastrointestinal diseases caused by abnormal SIgA level of infant intestinal tracts; wherein the content of the first and second substances,
the dairy product, comprising: a protein-providing material, a fat-providing material and bifidobacteria; wherein the content of the first and second substances,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains a-whey protein and beta-casein;
the fat-providing raw material contains at least palmitic acid glyceride, and the palmitic acid glyceride contains 15% or more (for example, 18% or more, 20% or more, 15% to 98%, 15% to 90%, 20% to 80%, 20% to 95%, 30%, 40%, 50%, 60%, 70%) by weight of Sn-2 palmitic acid glyceride;
the Bifidobacterium is selected from at least one of Bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and Bifidobacterium infantis.
In some embodiments of the invention, the protein providing material is 200 to 1600 parts by weight, such as 400 parts by weight, 700 parts by weight, 800 parts by weight, 900 parts by weight, 1000 parts by weight, 1200 parts by weight, 1500 parts by weight; the fat-providing raw material is 70 to 500 parts by weight, for example, 100 parts by weight, 200 parts by weight, 300 parts by weight, 400 parts by weight.
In some embodiments of the invention, the weight ratio of the a-lactalbumin, the beta-casein and the Sn-2 glyceryl palmitate in the dairy product is (1-10) to (1-10), such as 1 (1-2) to (1-2), 1 (1-5) to (1-5), (1-4) to 1 (1-5), 1 (1-7) to (1-6), 1.32.
In some embodiments of the invention, the dairy product has a viable count of bifidobacteria of 10 per gram of beta-casein 6 ～10 11 CFU, e.g. 10 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU。
In some embodiments of the invention, the bifidobacteria in the dairy product are selected from the group consisting of bifidobacterium BB12 and bifidobacterium HN019.
In some embodiments of the present invention, the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 in the dairy product is (1.
In some embodiments of the invention, the milk product is prepared from a fat-providing raw material selected from the group consisting of OPO structural fat, vegetable fat and animal fat.
In some embodiments of the invention, the vegetable oil is selected from the group consisting of sunflower oil, corn oil, rapeseed oil, and soybean oil.
In some embodiments of the invention, the fat providing feedstock comprises OPO structural fat, sunflower oil, corn oil, soybean oil and optionally rapeseed oil.
In some embodiments of the invention, the dairy product further comprises a carbohydrate-providing raw material.
In some embodiments of the invention, the carbohydrate is a carbohydrate commonly used in the art.
In some embodiments of the invention, the carbohydrate-providing source is selected from lactose, sucrose, glucose, starch and dextrin, preferably lactose.
In some embodiments of the invention, the carbohydrate-providing source is 100 to 600 parts by weight, such as 100 parts by weight, 150 parts by weight, 200 parts by weight, 250 parts by weight, 300 parts by weight, 350 parts by weight, 400 parts by weight, 450 parts by weight, 500 parts by weight, 560 parts by weight.
In some embodiments of the invention, the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids, and choline chloride.
Hair brushIn some embodiments of the invention, the viable count of bifidobacteria per hundred grams of dairy product is 10 3 ～10 15 CFU, e.g. 10 4 CFU、10 5 CFU、10 7 CFU、10 8 CFU、10 9 CFU、 10 10 CFU、10 11 CFU、10 12 CFU、10 13 CFU、10 14 CFU。
In some embodiments of the invention, the dairy product comprises the following raw materials:
the dairy product contains bifidobacterium BB12 and bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU), the viable count of bifidobacterium HN019 is 10 according to the weight of beta-casein per gram 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、 10 10 CFU)。
In some embodiments of the invention, the dairy product further comprises vitamins and/or minerals.
In some embodiments of the invention, the vitamin is present in an amount of 1 to 500mg per hundred grams of dairy product, e.g. 10mg, 20mg, 50mg, 100mg, 120mg, 150mg.
Some embodiments of the invention contain 10-3000 mg of minerals per hundred grams of dairy product, such as 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000mg.
In some embodiments of the invention, the vitamin is selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K 1 Vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Niacin, folic acid, pantothenic acid, and biotin.
In some embodiments of the invention, the mineral is selected from the group consisting of sodium, potassium, copper, magnesium, iron, zinc, calcium, phosphorus, iodine, selenium, and derivatives thereof.
Some embodiments of the invention include one or more of the following (a) to (d):
(a) The animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) The whey protein powder is selected from desalted whey protein powder, undesalted whey protein powder and a-whey protein powder;
preferably, the weight of the desalted whey protein powder is 1 to 20 times, for example 2, 5, 7, 9, 10, 12, 14, 15, 17, 19 times, the weight of the undesalted whey protein powder;
preferably, the weight of the undesalted whey protein powder is 0.5-40 times, such as 1, 2, 5, 10, 20, 25, 30, 35, 40 times the weight of the a-whey protein powder;
(c) The dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
preferably, the weight ratio of fructo-oligosaccharide to galacto-oligosaccharide is 1 (1-6), such as 1:2, 1:3, 1:4, 1:5;
(d) The phospholipid is soybean phospholipid.
In some embodiments of the invention, the animal milk is selected from the group consisting of raw milk, whole milk, low fat milk, and skim milk.
In some embodiments of the invention, the milk powder is selected from the group consisting of whole milk powder, low-fat milk powder, and skim milk powder, preferably whole milk powder and skim milk powder;
preferably, the weight ratio of the whole milk powder to the skim milk powder is (0.1-12) 1, such as 0.2.
In some embodiments of the invention, the dairy product comprises:
the dairy product also comprises bifidobacterium BB12 and bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU), the viable count of bifidobacterium HN019 is 10 according to the weight of beta-casein per gram 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、 10 10 CFU) containing 1 to 500mg (e.g. 10mg, 20mg, 50mg, 100mg, 120mg, 150 mg) of vitamins and 10 to 3000mg (e.g. 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000 mg) of minerals per hundred grams of dairy product.
In some embodiments of the invention, the dairy product is prepared by:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) Sterilizing the homogeneous material to obtain a sterilized material;
(4) Drying the sterilized material to obtain powder;
(5) And dry-mixing the powder, the bifidobacterium, the DHA and the ARA to obtain the dairy product.
Some embodiments of the invention include one or more of the following 1) to 11):
1) The method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) In the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) In the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) A step (2-2) is further included between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
preferably, the dry matter content of the concentrate is between 40% and 60% by weight;
5) In the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) In the step (3), the time of sterilization treatment is 10-60 seconds;
7) In the step (4), before drying treatment, filtering and removing impurities from the sterilized materials;
8) In the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
preferably, the air inlet temperature of the spray drying tower is 150-200 ℃;
preferably, the air exhaust temperature of the spray drying tower is 80-120 ℃;
preferably, the negative pressure of the spray drying tower is-10 to-2 mmWG;
preferably, the sterilizing material is introduced into the spray drying tower by means of a high-pressure pump;
more preferably, the pressure of the high-pressure pump is 140 to 250bar;
9) In the step (5), the dry mixing temperature is 20-35 ℃;
10 In step (5), dry mixing is carried out by means of a fluidized bed;
11 The method further comprises step (6): the dairy product is sieved.
In some embodiments of the invention, the food product is a dairy product.
Without being bound by theory, the intestinal SIgA level of breast-fed infants is generally superior to that of infants fed by artificial methods such as formula milk powder, which is a main reason for advocating breast-feeding for many years. The improvement of the intestinal SIgA level of the infants takes the intestinal SIgA level of breast-fed infants as an improvement target, namely the intestinal SIgA level (the SIgA content and the change trend of the SIgA content along with time) of the breast-fed infants is reached or approached. The abnormal SIgA level of the intestinal tract of the infant in the invention is deviated from the SIgA level of the intestinal tract of a breast-fed infant (SIg content and change trend thereof along with time) or has obvious difference with the SIgA level of the intestinal tract of the breast-fed infant.
In some embodiments of the first aspect of the invention, the immune disorder caused by an abnormal level of SIgA in the infant's intestine is selected from allergy and celiac disease.
In some embodiments of the first aspect of the invention, the gastrointestinal disorder caused by abnormal SIgA levels in the infant's intestinal tract is selected from inflammatory bowel disease (e.g. rotavirus enteritis) and gastrointestinal mucosal injury.
In the invention, the dairy product is selected from at least one of sterilized milk, reconstituted milk, yoghourt, yogurt, milk powder, formula milk powder, condensed milk, cheese, casein, whey powder, milk fat and milk-containing beverage, and is preferably infant formula milk powder.
In the present invention, unless otherwise specified, wherein:
the term "glyceryl palmitate" refers to fatty acid glycerides having at least one palmitic acid attached to a glyceryl moiety, and may be selected from monoesters, diesters and triesters, wherein other fatty acid moieties may also be attached to the glyceryl moieties of the diesters, triesters.
The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl moiety of a fat.
The term "Sn-2 glyceryl palmitate" refers to fatty acid glycerides with palmitic acid attached to the Sn-2 position of the glyceryl moiety, and may be selected from the group consisting of Sn-2 monoglycerides, sn-2 diglycerides and Sn-2 triglycerides; wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid, linolenic acid and the like.
The term "a-lactalbumin" is a protein extracted from milk, has the characteristics of high nutritional value, easy digestion and absorption, multiple active ingredients and the like, and is one of high-quality protein supplements for human bodies.
The term "beta-casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells and is widely found in the milk of mammals (cows, yaks, goats, horses, rabbits, etc.) and humans.
The term "OPO structure fat" is actually a structured fat, and the molecular structure of breast milk fat is simulated by an enzymatic lipid exchange technology, so that the proportion of 2-position palmitic acid is up to more than 40 percent and is closer to the level of breast milk.
The invention has the following beneficial effects:
the dairy product provided by the invention can improve the SIgA level of the infant intestinal tract, and prevent or treat immune diseases or gastrointestinal diseases caused by abnormal SIgA level of the infant intestinal tract.
Drawings
In order that the present disclosure may be more readily understood, a more particular description of the disclosure will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings
Fig. 1 is a graph showing SIgA levels in feces of infants in the test group, the control group, and the breast-milk group at different time points.
Detailed Description
The embodiments of the present invention will now be described more fully hereinafter with reference to the accompanying examples, in which some, but not all embodiments of the invention are shown. The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), a-whey protein powder (purity 77 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), beta-casein, soybean phospholipid, choline chloride and compound nutrients (the components are shown in tables 1-2) uniformly according to the formula in table 1-1, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby material to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 1 with uniform particles, and filling nitrogen for packaging.
In the formula milk powder 1, the palmitic acid glyceride contains 22% of Sn-2 palmitic acid glyceride by weight, the weight ratio of a-lactalbumin, beta-casein and Sn-2 palmitic acid glyceride is 2.4, the formula milk powder contains 1.6wt.% of a-lactalbumin, and the sum of the viable count of two bifidobacteria is 2 multiplied by 10 according to the weight of each gram of a-lactalbumin 7 CFU。
Table 1-1 formulation of example 1
Table 1-2 ingredients contained in the Complex Nutrients
Example 2
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 34 wt.%), desalted whey powder (purity 12 wt.%), a-whey protein powder (purity 77 wt.%), OPO structure fat, high-oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), beta-casein, soybean phospholipid, choline chloride and compound nutrients (the components are shown in Table 2-2) uniformly according to the formula in Table 2-1, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 2 with uniform particles, and filling nitrogen for packaging.
In the formula milk powder 2, the palmitic acid glyceride contains 22% of Sn-2 palmitic acid glyceride by weight, the weight ratio of a-lactalbumin, beta-casein and Sn-2 palmitic acid glyceride is 2.5 7 CFU。
TABLE 2-1 formulation of example 2
TABLE 2-2 ingredients contained in the Complex Nutrients
Comparative example
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, rapeseed oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo oligosaccharide (from chicory), soybean phospholipid, choline chloride and compound nutrients (the components are shown in table 3-2) uniformly according to the formula in table 3-1, and removing impurities by using a mixed material filter screen to obtain an impurity-removed material;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA and ARA at 25-30 ℃ by a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder by using a vibrating screen to obtain formula milk powder A with uniform particles, and filling nitrogen for packaging.
In formula A, the palmitic acid glyceride contains 12.5% by weight of Sn-2 palmitic acid glyceride, and is substantially free of a-lactalbumin, beta-casein, and bifidobacteria.
TABLE 3-1 formulation of comparative example
| Components | Dosage (kg) |
| Whole milk powder | 230 |
| Defatted milk powder | 100 |
| Lactose | 305 |
| Whey protein powder (purity 80 wt.%) | 50 |
| Desalted whey powder ( |
170 |
| OPO structural fat | 100 |
| High oleic sunflower oil | 40 |
| Corn oil | 30 |
| Soybean oil | 70 |
| Rapeseed oil | 60 |
| Galacto-oligosaccharide syrup (purity 57 wt.%) and | 45 |
| fructo-oligosaccharide (chicory source) | 10 |
| Soybean lecithin | 1.4 |
| Choline chloride | 0.9 |
| DHA | 6 |
| ARA | 6 |
| Compound nutrient | 13.4 |
TABLE 3-2 ingredients contained in the Complex Nutrients
Clinical test method and test results
The feeding effect of the formula of example 1 and the formula of the comparative example were compared in a random control design.
1. Grouping of subjects:
infants in need of inclusion were screened by recruiting screening questionnaires by pediatricians or trained researchers. Written informed consent was obtained from the mother prior to study entry.
1.1 inclusion criteria
And (3) full-term infants: the gestational week is more than or equal to 37 weeks;
birth weight: 2.5kg-4kg;
normal pregnancy, delivered baby (including cesarean section);
healthy, apgar score > 7 after birth for 5-10 minutes;
age: < 15 days.
1.2 exclusion criteria
Infants with any of the following characteristics were excluded:
congenital malformations or chromosomal disorders detected at birth and of clinical significance;
patients with disease requiring mechanical ventilation or medication within one week after birth (infant jaundice patients who do not include blue light therapy);
those who affect feeding or metabolism due to suspected or unknown metabolic factors or due to physical defects;
twins or multiple births.
1.3 Experimental groups
Infants of 0-6 months old and full-term are selected as study objects, the infants are fed with the infant formula milk powder, the feeding amount of the infant formula milk powder of 1-15 days old is more than or equal to 250ml/d, the infants with the dry starting prognosis milk powder feeding rate of more than 80% are randomly divided into a test group (fed with the formula milk powder of example 1) and a control group (fed with the formula milk powder of a comparative example). The number of people in each group is not less than 5.
2. Intervention study method
Baseline (postnatal day 15) surveys and sample collections were conducted on enrolled infants, followed by continuous feeding for 6 months, during which time the subject was followed by visits by the project investigator at 4, 6, 8, 16, and 24 weeks after the start of feeding. The immunization of the infants was investigated.
3. Results of clinical experiments
Infants in the breast-milk group, test group and control group were tested for SIgA levels in stool output at baseline (day 15 after birth), at 6 weeks, 16 weeks, and 24 weeks after feeding, and the results are shown in fig. 1, where "diamond-solid" indicates the breast-milk group, "■" indicates the test group, and "tangle-solidup" indicates the control group.
As can be seen from FIG. 1, the overall level and the time-dependent trend of SIgA in the feces of the infants in the test group are similar to those of the infants in the breast milk group, which indicates that the immune status of the test group and the infants in the breast milk group progresses similarly; however, there was a significant statistical difference in the time-dependent trend of SIgA in the feces of the test group compared to the time-dependent trend of SIgA of the control group (p < 0.001). The trend of SIgA changes more closely to breast-fed infants in the test group. Since it is generally known to those skilled in the art that breast-feeding is beneficial for improving the immune system of infants, and the intestinal SIgA is an important immune substance, it can be seen that the SIgA level in the intestinal tract of breast-fed infants reflects the well-being of the immune system of healthy infants. The intestinal SIgA level and the change trend of the infants in the test group and the breast milk group are similar, which shows that the milk powder fed in the test group is also beneficial to improving the immune system condition of the infants. Therefore, compared with the control group milk powder, the formula milk powder is more beneficial to improving the immune system of infants and preventing or treating the immune system diseases of infants.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Reference to the literature
[1]Ventura M,Milani C,Lugli GA,van Sinderen D.Health benefits conferred by the human gut microbiota during infancy.Microb Biotechnol.2019Mar；12(2):243-248.
[2]Husby S,et al.European Society for Pediatric Gastroenterology,Hepatology,and Nutrition guidelines for the diagnosis of coeliac disease.J Pediatr Gastroenterol Nutr.
2012；54(1):136–60.
[3]Pabst O,Cerovic V,Hornef M.Secretory IgA in the Coordination of Establishment and Maintenance of the Microbiota.Trends Immunol.2016May；37(5):287-296.
[4]Crivelli C,Demarta A,Peduzzi R.Intestinal secretory immunoglobulin A(sIgA) response to Aeromonas exoproteins in patients with naturally acquired Aeromonas diarrhea.FEMS Immunol Med Microbiol.2001Feb；30(1):31-5。
Claims (25)
1. The use of a milk product in the preparation of a medicament for the prevention or treatment of immune or gastrointestinal disorders caused by abnormal elevation of SIgA levels in the infant's intestinal tract; wherein the immune diseases caused by abnormal increase of the infant intestinal SIgA level are selected from allergy and celiac disease, and the gastrointestinal diseases caused by abnormal increase of the infant intestinal SIgA level are selected from inflammatory bowel disease and gastrointestinal tract mucosal injury;
wherein the dairy product comprises: a protein-providing material, a fat-providing material and bifidobacteria; wherein the content of the first and second substances,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains alpha-lactalbumin and beta-casein;
the raw material for providing fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains 30% by weight or more of Sn-2 palmitic acid glyceride;
the Bifidobacterium is Bifidobacterium BB12 and Bifidobacterium HN019;
wherein, in the dairy product, its characterized in that:
the weight ratio of the alpha-lactalbumin to the beta-casein to the Sn-2 glyceryl palmitate is (1-10) to (1-10);
the viable count of the bifidobacteria is 10 according to the weight of beta-casein per gram 6 ～10 11 CFU；
Wherein the ratio of viable count of bifidobacterium BB12 to viable count of bifidobacterium HN019 is (1.
2. Use of a dairy product for the preparation of a food product for improving the intestinal SIgA level of an infant closer to that of a breast-fed infant;
wherein the dairy product comprises: a protein providing material, a fat providing material and bifidobacteria; wherein the content of the first and second substances,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains alpha-whey protein and beta-casein;
the raw material for providing fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains 30% by weight or more of Sn-2 palmitic acid glyceride;
the Bifidobacterium is Bifidobacterium BB12 and Bifidobacterium HN019;
wherein, in the dairy product, its characterized in that:
the weight ratio of the alpha-lactalbumin to the beta-casein to the Sn-2 glyceryl palmitate is (1-10) to (1-10);
the viable count of the bifidobacteria is 10 according to the weight of beta-casein per gram 6 ～10 11 CFU；
Wherein the ratio of viable count of bifidobacterium BB12 to viable count of bifidobacterium HN019 is (1.
3. The use according to claim 1, wherein the protein-providing material is 200 to 1600 parts by weight and the fat-providing material is 70 to 500 parts by weight.
4. Use according to claim 1 or 3, wherein in the dairy product, the fat-providing raw material is selected from OPO structural fat, vegetable fat and oil and animal fat and oil.
5. Use according to claim 4, wherein the vegetable oil is selected from sunflower oil, corn oil, rapeseed oil and soybean oil.
6. Use according to claim 1 or 3, wherein the milk product further comprises a carbohydrate providing raw material.
7. Use according to claim 6, wherein the carbohydrate-providing raw material is selected from lactose, sucrose, glucose, starch and dextrin.
8. Use according to claim 6, wherein the carbohydrate-providing raw material is 100 to 600 parts by weight.
9. The use according to claim 1, wherein the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids and choline chloride.
10. Use according to claim 1, wherein the dairy product comprises:
the dairy product contains bifidobacterium BB12 and bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 per gram of beta-casein 6 ～10 11 The viable count of CFU and bifidobacterium HN019 is 10 in terms of per gram of beta-casein 6 ～10 11 CFU。
11. Use according to claim 10, wherein the milk product further comprises vitamins and/or minerals.
12. Use according to claim 11, wherein the vitamin is present in an amount of 1 to 500mg per hundred grams of dairy product.
13. Use according to claim 11, wherein 10-3000 mg mineral is present per hundred grams dairy product.
14. Use according to any one of claims 9 to 13, wherein the dairy product is characterized by one or more of the following (a) to (d):
(a) The animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) The lactalbumin powder is selected from desalted lactalbumin powder, undesalted lactalbumin powder and alpha-lactalbumin powder;
(c) The dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
(d) The phospholipid is soybean phospholipid.
15. The use according to claim 14, wherein in item (b), the weight of the desalted whey protein powder is 1 to 20 times of the weight of the undesalted whey protein powder.
16. The use according to claim 14, wherein in item (b), the weight of the undesalted whey protein powder is 0.5-40 times of the weight of the alpha-whey protein powder.
17. The use according to claim 14, wherein in item (c), the weight ratio of fructo-oligosaccharide to galacto-oligosaccharide is 1 (1-6).
18. Use according to any one of claims 10 to 13, wherein the milk product is prepared by a process comprising the steps of:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) Sterilizing the homogeneous material to obtain a sterilized material;
(4) Drying the sterilized material to obtain powder;
(5) And dry-mixing the powder, the bifidobacteria, the DHA and the ARA to obtain the dairy product.
19. Use according to claim 18, wherein in the process of preparing a dairy product, one or more of the following 1) to 11) are characterized:
1) The method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) In the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) In the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) A step (2-2) is further included between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
5) In the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) In the step (3), the time of sterilization treatment is 10-60 seconds;
7) In the step (4), before drying treatment, filtering and removing impurities from the sterilized materials;
8) In the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
9) In the step (5), the dry mixing temperature is 20-35 ℃;
10 In step (5), dry mixing is carried out by means of a fluidized bed;
11 The method further comprises step (6): the dairy product is screened.
20. Use according to claim 19, wherein in item 4), the dry matter content of the concentrate in step (2-2) is between 40% and 60% by weight.
21. The use according to claim 19, wherein, in the step (4), the temperature of the inlet air of the spray drying tower is 150-200 ℃.
22. The use according to claim 19, wherein in item 8), the temperature of the air discharge of the spray drying tower in step (4) is 80 ℃ to 120 ℃.
23. The use according to claim 19, wherein, in the step (4), the negative pressure of the spray drying tower is-10 to-2 mmWG in the 8).
24. The use according to claim 19, wherein, in item 8), the sterilizing material is introduced into the spray-drying tower by means of a high-pressure pump in step (4).
25. The use according to claim 24, wherein, in item 8), the pressure of the high-pressure pump in step (4) is 140 to 250bar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010104555.6A CN111227046B (en) | 2020-02-20 | 2020-02-20 | Application of dairy product in improving infant intestinal SIgA level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010104555.6A CN111227046B (en) | 2020-02-20 | 2020-02-20 | Application of dairy product in improving infant intestinal SIgA level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111227046A CN111227046A (en) | 2020-06-05 |
| CN111227046B true CN111227046B (en) | 2023-04-11 |
Family
ID=70868058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010104555.6A Active CN111227046B (en) | 2020-02-20 | 2020-02-20 | Application of dairy product in improving infant intestinal SIgA level |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111227046B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012010488A (en) * | 2012-09-11 | 2014-03-26 | Nucitec Sa De Cv | Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants. |
| AU2018101868A4 (en) * | 2017-12-01 | 2019-01-17 | Noumi Ip Pty Ltd | Milk Substitute Compositions |
-
2020
- 2020-02-20 CN CN202010104555.6A patent/CN111227046B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111227046A (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111227044B (en) | Dairy product, preparation method and medical application thereof | |
| CN1838888B (en) | Baby or second stage formula milk | |
| US9144250B2 (en) | Nutritional formulation for promoting catch-up growth | |
| US8394370B2 (en) | Nutritional formula for optimal gut barrier function | |
| EP2378890B1 (en) | Prevention and treatment of rotavirus diarrhoea | |
| EP1976397B1 (en) | Infant immunological formula | |
| US20130189398A1 (en) | Nutritional Composition for Children with Reflux, Colic and/or Constipation | |
| US9474298B2 (en) | Partially hydrolyzed casein-whey nutritional compositions for reducing the onset of allergies | |
| US20170182132A1 (en) | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions | |
| JP2016505024A5 (en) | ||
| JP2016505024A (en) | Baby food composition containing bacteria that produce viable propionic acid | |
| MX2013005943A (en) | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions. | |
| CN111227046B (en) | Application of dairy product in improving infant intestinal SIgA level | |
| Falcão et al. | Infant Formulas: A Long Story | |
| JP7482875B2 (en) | Food-grade butyrate for treating or preventing allergic diseases | |
| TW201822640A (en) | Compositions comprising maltotriose and methods of using same to inhibit damage caused by dehydration processes | |
| CN114760859A (en) | Dietary butyrate | |
| JP2022533921A (en) | Food grade butyrate and its use | |
| CN117580465A (en) | Nutritional composition for human consumption and method for preparing the same | |
| CN112839529A (en) | Nutritional compositions, their use in reducing metabolic stress and methods of reducing metabolic stress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |